AC Immune (ACIU) Current Deferred Revenue (2014 - 2024)
AC Immune (ACIU) posted quarterly Current Deferred Revenue of $104.7 million for Q4 2025, up 7.87% year-over-year from $97.1 million in Q4 2024, and up 3.56% quarter-over-quarter from $101.1 million in Q2 2025.
Powered by 
Analysis
AC Immune (ACIU) Current Deferred Revenue (2014 - 2024) Analysis & Trends
AC Immune (ACIU) has reported Current Deferred Revenue for 12 consecutive years, with $104.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Deferred Revenue rose 7.87% year-over-year to $104.7 million; the TTM figure through Dec 2025 stood at $104.7 million (up 7.87% YoY), while the FY2025 annual figure was $101.0 million, up 3.98% from the prior year.
- Current Deferred Revenue grew to $104.7 million in Q4 2025 per ACIU's latest filing, from $101.1 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $777.6 million in Q4 2021 and bottomed at $18467.3 in Q3 2024.
- Historically, Current Deferred Revenue has averaged $166.2 million across 5 years, with a median of $48.9 million in 2024.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue jumped 229626.92% — and 2022, when it plunged 99.92%.
- AC Immune's Current Deferred Revenue stood at $777.6 million in 2021, then slumped by 99.92% to $609318.9 in 2022, then surged by 25432.59% to $155.6 million in 2023, then slumped by 37.59% to $97.1 million in 2024, then grew by 7.87% to $104.7 million in 2025.
- Business Quant data shows ACIU's Current Deferred Revenue at $104.7 million in Q4 2025, $101.1 million in Q2 2025, and $97.1 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 84,780.49 |
| Dec 31, 2023 | 155,574.92 |
| Sep 30, 2023 | 382,667.57 |
| Jun 30, 2023 | 478,235.49 |
| Mar 31, 2023 | 448,682.47 |
| Dec 31, 2022 | 609,318.86 |
| Sep 30, 2022 | 542,579.28 |
| Jun 30, 2022 | 441,274.53 |
| Mar 31, 2022 | 288,027.03 |
| Dec 31, 2021 | 777,588.00 |
| Dec 31, 2020 | 338,483.62 |
| Dec 31, 2019 | 4.52 Mn |
| Dec 31, 2018 | 352,697.01 |
| Sep 30, 2018 | 42,688.34 |
| Jun 30, 2018 | 475,466.92 |
| Mar 31, 2018 | 43,230.65 |
| Dec 31, 2017 | 359,820.64 |
| Sep 30, 2017 | 41,572.04 |
| Jun 30, 2017 | 346,114.56 |
| Mar 31, 2017 | 127,483.33 |